<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29617501</article-id><article-id pub-id-type="pmc">5873784</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2017-0138</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>CABG and Preoperative use of Beta-Blockers in Patients with Stable
Angina are Associated with Better Cardiovascular Survival</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Dayan</surname><given-names>Victor</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Perez</surname><given-names>Diego</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Silva</surname><given-names>Eloisa</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Soca</surname><given-names>Gerardo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Estigarribia</surname><given-names>Jorge</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><aff id="aff1">
<label>1</label> Instituto Nacional de Cirug&#x000ed;a Card&#x000ed;aca,
Montevideo, Uruguay. </aff></contrib-group><author-notes><corresp id="c1">Correspondence Address: Victor Dayan, 26 de Marzo 3459/602 -
Montevideo, Uruguay. E-mail: <email>victor_dayan@hotmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Jan-Feb</season><year>2018</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Jan-Feb</season><year>2018</year></pub-date><volume>33</volume><issue>1</issue><fpage>47</fpage><lpage>53</lpage><history><date date-type="received"><day>07</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>19</day><month>9</month><year>2017</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>In contrast to unstable angina, optimal therapy in patients with stable
angina is debated. Our aim was to evaluate the outcomes of patients with
stable angina scheduled for isolated coronary artery bypass grafts and the
effect of preoperative use of beta-blockers. Overall and cardiovascular
survivals were our primary outcome. Operative mortality and postoperative
complications along with subgroup analysis of diabetic patients were our
secondary outcomes.</p></sec><sec><title>Methods</title><p>Retrospective evaluation of patients with stable angina scheduled for
isolated coronary artery bypass grafts was included. Pre- and postoperative
variables were extracted from the institution database. Survival was
obtained from the National Registry.</p></sec><sec><title>Results</title><p>We included 282 patients with stable angina, with a mean age of
65.6&#x000b1;9.5 years. 26.6% were female and 38.7% had diabetes.
Three-vessel disease was present in 76.6% of patients. Previous beta-blocker
treatment was evident in 69.9% of patients. 10-year overall survival in the
whole population was 60.5% (95% confidence interval [CI]:
50.3-70.7%). Operative mortality during the study period was 3.5%. Patients
with preoperative use of beta-blocker therapy had better overall survival
(9.0 years, 95%CI: 8.6-9.5) than those without treatment (7.9 years, 95%CI:
7.1-8.8 years; <italic>P</italic>=0.048). Predictors for overall survival
were: hypertension, diabetes, and age. Predictors for cardiovascular
survival in diabetic patients were: beta-blocker use, gender, and age.</p></sec><sec><title>Conclusion</title><p>Coronary artery bypass grafts surgery in patients with stable angina carries
low operative mortality, postoperative complications, and excellent
long-term cardiovascular survival. The preoperative use of beta-blockers in
diabetic patients is associated with better cardiovascular survival after
coronary artery bypass grafts.</p></sec></abstract><kwd-group><kwd>Coronary artery bypass</kwd><kwd>Adrenergic betaantagonists/therapeutic use</kwd><kwd>Angina, stable</kwd><kwd>Preoperative Care/methods</kwd></kwd-group></article-meta></front><body><table-wrap id="t7" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="20%" span="1"/><col width="80%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ACS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Acute coronary
syndromes</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AMI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Acute myocardial
infarction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafts</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CAD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery
disease</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Confidence interval</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">COPD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Chronic obstructive
pulmonary disease</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary
bypass</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">HR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Hazard ratio</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IMA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Internal mammary
artery</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">INCC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Instituto Nacional de
Cirug&#x000ed;a Card&#x000ed;aca</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">OPCABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Off-pump coronary artery
bypass graft</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PCI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Percutaneous coronary
intervention</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">PTCA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Percutaneous
transluminal coronary angioplasty</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Standard deviation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TTFM</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transit time flow
measurement</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Patients with stable angina (SA) represent the largest group of patients with
coronary artery disease (CAD). These patients may be treated with medical therapy
alone or in combination with revascularization by either coronary artery bypass
grafts (CABG) or percutaneous coronary intervention (PCI)<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. Multiple randomized
controlled trials have compared the efficacy of revascularization
<italic>versus</italic> optimal contemporary medical therapy<sup>[<xref rid="r2" ref-type="bibr">2</xref>-<xref rid="r4" ref-type="bibr">4</xref>]</sup>. Although these studies have shown no difference between
them, their main drawback is the restrictive recruitment strategies and unrealistic
levels of medication compliance and lifestyle modification<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. Thus, there is substantial
uncertainty as to the generalizability of randomized control trials findings to
routine clinical practice. On the other hand, recent metaanalysis have highlighted
improved survival in patients after revascularization<sup>[<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p><p>The main arguments against CABG in patients with stable angina are operative
mortality and postoperative complications. We aimed to study 5 and 10-year
survivals, postoperative complications and predictors of survival in a local cohort
of patients with stable angina scheduled for isolated CABG (primary outcome).
Furthermore, we evaluated the effect of preoperative use of beta-blockers and
performed subgroup analysis with diabetic patients (secondary outcome).</p></sec><sec sec-type="methods"><title>METHODS</title><sec><title>Patients</title><p>The study was approved by the Instituto Nacional de Cirug&#x000ed;a
Card&#x000ed;aca (INCC) review board and informed consent was waived due to its
retrospective nature. Patients with stable angina who underwent isolated CABG
from January 2006 and December 2014 were included. Exclusion criteria used were:
emergency/urgency and left main stenosis. During that period, 352 patients
underwent surgery for isolated stable angina. From these, 70 patients had left
main stenosis or were operated under emergency/urgency basis. We included 282
patients with stable angina who underwent isolated CABG in a non-urgent or
emergent basis.</p><p>Basal demographic characteristics, postoperative outcomes (operative mortality,
hemodialysis, pneumonia, and stroke), and survival were included for each
patient.</p><p>Operative mortality was defined as death 30 days after surgery or during primary
hospitalization. Postoperative complications are defined as those which arise
during the first 30 days after surgery. At discharge, all patients were
prescribed with the same medication protocol which is adjusted individually.
Basically, all patients receive statins, beta-blockers, and aspirin. Adherence
to medication could only be evaluated after one-month of surgery (when the last
clinical control was performed) and 100% of patients adhered to the
prescription.</p><p>Follow-up was achieved in 100% of patients. Mortality data was obtained through
the governmental agency National Resources Fund (Fondo Nacional de
Recursos).</p></sec><sec><title>Surgery</title><p>A median sternotomy was performed in all patients. CABG surgery was performed
with cardiopulmonary bypass (CPB) in a standardized fashion using ascending
aortic cannulation and two-stage venous cannulation of the right atrium.
Intermittent cold crystalloid Buckberg cardioplegia was delivered antegrade via
the aortic root. Off-pump or beating heart procedures were performed achieving
stabilization using Medtronic Octopus and Starfish stabilizers. Grafting was
attempted on all vessels measuring 1 mm or more in diameter with a 50% or
greater stenosis.</p><p>Graft patency was measured using transit time flow measurement (TTFM) (VeriQ,
Medisitim) as previously described by D'Ancona et al.<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>. Measurements were
performed after weaning of CPB and with systolic blood pressure between 120-140
mmHg. Revision of anastomosis was performed when pulsatility index was higher
than 5.</p></sec><sec><title>Outcomes</title><p>Overall and cardiovascular survivals were our primary outcome. Operative
mortality and postoperative complications along with subgroup analysis of
diabetic patients were our secondary outcome. Impact of multiple bypass using
internal mammary artery (IMA) was evaluated comparing survival in patients who
received one or more than one IMA bypass.</p></sec><sec><title>Statistical Analysis</title><p>Continuous variables were expressed as mean &#x000b1; standard deviation (SD) and
compared using Student t-test. Categorical variables were expressed as absolute
numbers (%) and compared using Chi-square test. Survival was analyzed with
Kaplan-Meier and log-rank test. Cox regression was used to evaluate independent
predictors for overall and cardiovascular survivals. Variables with
<italic>P</italic>&#x0003c;0.1 after univariate analysis were entered in the
multivariate analysis.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Mean age was 65.6&#x000b1;9.5 years; 26.6% were female and 38.7% had diabetes.
Previous percutaneous transluminal coronary angioplasty (PTCA) was present in 14.9%
of patients and 76.6% of patients had three-vessel disease. Previous beta-blocker
treatment was evident in 69.9% of patients (<xref ref-type="table" rid="t1">Table
1</xref>). Pre- and operative variables were similar between patients with and
without beta-blockers, except for higher incidence of chronic obstructive pulmonary
disease (COPD) and off-pump coronary artery bypass graft (OPCABG) in the latter
group (<xref ref-type="table" rid="t2">Table 2</xref>).</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Basal demographics of included patients (n=282).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">Patients (282)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (SD)</td><td align="center" rowspan="1" colspan="1">65.6 (9.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Female (%)</td><td align="center" rowspan="1" colspan="1">75 (26.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoker (%)</td><td align="center" rowspan="1" colspan="1">71 (25.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension (%)</td><td align="center" rowspan="1" colspan="1">222 (78.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes (%)</td><td align="center" rowspan="1" colspan="1">109 (38.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyslipidemia (%)</td><td align="center" rowspan="1" colspan="1">243 (86.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">PVD (%)</td><td align="center" rowspan="1" colspan="1">19 (6.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">COPD (%)</td><td align="center" rowspan="1" colspan="1">7 (2.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke (%)</td><td align="center" rowspan="1" colspan="1">11 (3.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">AMI (%)</td><td align="center" rowspan="1" colspan="1">__</td></tr><tr><td align="left" rowspan="1" colspan="1">Preoperative creatinine (mg/dl)</td><td align="center" rowspan="1" colspan="1">1.4 (5.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEF (%)</td><td align="center" rowspan="1" colspan="1">55.3 (12.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous PTCA (%)</td><td align="center" rowspan="1" colspan="1">42 (14.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous CABG (%)</td><td align="center" rowspan="1" colspan="1">3 (1.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA III-IV (%)</td><td align="center" rowspan="1" colspan="1">18 (11.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Angina CCS III</td><td align="center" rowspan="1" colspan="1">67 (25.3)</td></tr><tr><td align="left" rowspan="1" colspan="1">Vessel disease (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1</td><td align="center" rowspan="1" colspan="1">23 (8.1)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2</td><td align="center" rowspan="1" colspan="1">43 (15.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;3</td><td align="center" rowspan="1" colspan="1">216 (76.6)</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;1 IMA bypass (%)</td><td align="center" rowspan="1" colspan="1">75 (26.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">OPCABG (%)</td><td align="center" rowspan="1" colspan="1">57 (20.2)</td></tr><tr><td align="left" rowspan="1" colspan="1">Beta-blockers (%)</td><td align="center" rowspan="1" colspan="1">197 (69.9)</td></tr><tr><td align="left" rowspan="1" colspan="1">Statins (%)</td><td align="center" rowspan="1" colspan="1">84 (29.8)</td></tr><tr><td align="left" rowspan="1" colspan="1">Anti-aggregation (%)</td><td align="center" rowspan="1" colspan="1">233 (82.6)</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>AMI=acute myocardial infarction; CABG=coronary artery bypass grafts;
CCF=Canadian Cardiovascular Society; COPD=chronic obstructive pulmonary
disease; IMA=internal mammary artery; LVEF=left ventricular ejection
fraction; NYHA=New York Heart Association; OPCABG=Off-pump coronary
artery bypass graft; PTCA=percutaneous transluminal coronary
angioplasty; PVD=peripheral vascular disease; SD=standard deviation</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Demographic comparison between patients with and without preoperative beta
blockers (n=282).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="center" rowspan="1" colspan="1">BB (197)</th><th align="center" rowspan="1" colspan="1">No BB (85)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (SD)</td><td align="center" rowspan="1" colspan="1">65.2 (9.6)</td><td align="center" rowspan="1" colspan="1">66.5 (9.3)</td><td align="center" rowspan="1" colspan="1">0.302</td></tr><tr><td align="left" rowspan="1" colspan="1">Female (%)</td><td align="center" rowspan="1" colspan="1">53 (26.9)</td><td align="center" rowspan="1" colspan="1">22 (25.9)</td><td align="center" rowspan="1" colspan="1">0.859</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoker (%)</td><td align="center" rowspan="1" colspan="1">45 (22.8)</td><td align="center" rowspan="1" colspan="1">26 (36.6)</td><td align="center" rowspan="1" colspan="1">0.169</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension (%)</td><td align="center" rowspan="1" colspan="1">154 (78.2)</td><td align="center" rowspan="1" colspan="1">68 (80)</td><td align="center" rowspan="1" colspan="1">0.731</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes (%)</td><td align="center" rowspan="1" colspan="1">71 (36)</td><td align="center" rowspan="1" colspan="1">38 (44.7)</td><td align="center" rowspan="1" colspan="1">0.170</td></tr><tr><td align="left" rowspan="1" colspan="1">Dyslipidemia (%)</td><td align="center" rowspan="1" colspan="1">170 (86.3)</td><td align="center" rowspan="1" colspan="1">73 (85.9)</td><td align="center" rowspan="1" colspan="1">0.927</td></tr><tr><td align="left" rowspan="1" colspan="1">PVD (%)</td><td align="center" rowspan="1" colspan="1">8 (4.1)</td><td align="center" rowspan="1" colspan="1">4 (4.7)</td><td align="center" rowspan="1" colspan="1">0.806</td></tr><tr><td align="left" rowspan="1" colspan="1">COPD (%)</td><td align="center" rowspan="1" colspan="1">2 (1)</td><td align="center" rowspan="1" colspan="1">5 (5.9)</td><td align="center" rowspan="1" colspan="1">0.016*</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke (%)</td><td align="center" rowspan="1" colspan="1">7 (3.6)</td><td align="center" rowspan="1" colspan="1">4 (4.7)</td><td align="center" rowspan="1" colspan="1">0.646</td></tr><tr><td align="left" rowspan="1" colspan="1">AMI (%)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">Preoperative creatinine (mg/dl)</td><td align="center" rowspan="1" colspan="1">1.06 (0.42)</td><td align="center" rowspan="1" colspan="1">1.13 (1.14)</td><td align="center" rowspan="1" colspan="1">0.444</td></tr><tr><td align="left" rowspan="1" colspan="1">LVEF (%)</td><td align="center" rowspan="1" colspan="1">55.8 (11.4)</td><td align="center" rowspan="1" colspan="1">54.2 (13.9)</td><td align="center" rowspan="1" colspan="1">0.306</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous PTCA (%)</td><td align="center" rowspan="1" colspan="1">28 (14.2)</td><td align="center" rowspan="1" colspan="1">14 (16.5)</td><td align="center" rowspan="1" colspan="1">0.625</td></tr><tr><td align="left" rowspan="1" colspan="1">Previous CABG (%)</td><td align="center" rowspan="1" colspan="1">3 (1.5)</td><td align="center" rowspan="1" colspan="1">__</td><td align="center" rowspan="1" colspan="1">0.253</td></tr><tr><td align="left" rowspan="1" colspan="1">NYHA III-IV (%)</td><td align="center" rowspan="1" colspan="1">8 (7.2)</td><td align="center" rowspan="1" colspan="1">10 (21.2)</td><td align="center" rowspan="1" colspan="1">0.042</td></tr><tr><td align="left" rowspan="1" colspan="1">Angina CCS III</td><td align="center" rowspan="1" colspan="1">46 (25)</td><td align="center" rowspan="1" colspan="1">21 (25.9)</td><td align="center" rowspan="1" colspan="1">0.638</td></tr><tr><td align="left" rowspan="1" colspan="1">Vessel disease (%)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">0.139</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;1</td><td align="center" rowspan="1" colspan="1">7 (3.6)</td><td align="center" rowspan="1" colspan="1">3 (3.5)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;2</td><td align="center" rowspan="1" colspan="1">25 (12.7)</td><td align="center" rowspan="1" colspan="1">18 (21.2)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x000a0;&#x000a0;&#x000a0;&#x000a0;3</td><td align="center" rowspan="1" colspan="1">158 (80.2)</td><td align="center" rowspan="1" colspan="1">58 (68.2)</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x0003e;1 IMA bypass (%)</td><td align="center" rowspan="1" colspan="1">54 (27.4)</td><td align="center" rowspan="1" colspan="1">21 (24.8)</td><td align="center" rowspan="1" colspan="1">0.893</td></tr><tr><td align="left" rowspan="1" colspan="1">OPCABG (%)</td><td align="center" rowspan="1" colspan="1">9 (10.6)</td><td align="center" rowspan="1" colspan="1">48 (24.4)</td><td align="center" rowspan="1" colspan="1">0.008*</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>AMI=acute myocardial infarction; BB=beta-blockers; CABG=coronary artery
bypass grafts; CCS=Canadian Cardiovascular Society; COPD=chronic
obstructive pulmonary disease; IMA=internal mammary artery; LVEF=left
ventricular ejection fraction; NYHA=New York Heart Association;
OPCABG=Off-pump coronary artery bypass graft; PTCA=percutaneous
transluminal coronary angioplasty; PVD=peripheral vascular disease;
SD=standard deviation </p></fn></table-wrap-foot></table-wrap><sec><title>Primary Outcome</title><p>Overall 5 and 10-year survivals in the whole population were 85.3% (95%
confidence interval [CI]: 81.0-89.6%) and 60.5% (95%CI:
50.3-70.7%), respectively. 5 and 10-year cardiovascular survivals in the whole
population were 93.1% (95%CI: 90.096.2%) and 91.8% (95%CI: 88.3-95.3%),
respectively. Mean overall survival (7.9 years, 95%CI: 7.3-8.7 years) in
diabetic patients was significantly lower compared to non-diabetic patients (9.2
years, 95%CI: 8.7-9.7 years; <italic>P</italic>=0.004). Similar differences were
obtained for cardiovascular survival in diabetic (9.3 years, 95%CI: 9.6-9.9
years) and non-diabetic patients (10.1 years, 95%CI: 9.8-10.4;
<italic>P</italic>=0.038). Patients with preoperative use of beta-blocker
therapy had better overall survival (9.0 years, 95%CI: 8.6-9.5) than those
without treatment (7.9 years, 95%CI: 7.1-8.8 years; <italic>P</italic>=0.048).
Cardiovascular survival was also improved with preoperative use of beta-blockers
(10.1 years, 95%CI: 9.8-10.4 <italic>vs.</italic> 9.1 years, 95%CI: 8.4-9.8
years; <italic>P</italic>=0.03) (<xref ref-type="fig" rid="f1">Figure 1</xref>).
Patients with hypertension (8.5 years, 95%CI: 8.0-8.9 <italic>vs.</italic> 9.5
years, 95%CI: 8.9-10.1; <italic>P</italic>=0.011) were found to have worse
long-term overall survival. More than one bypass (multiple) using IMA was
associated with improved long term overall survival (9.3 years, 95%CI: 8.6-10.0
years <italic>vs.</italic> 8.3 years, 95%CI: 7.9-8.8 years;
<italic>P</italic>=0.04) (<xref ref-type="fig" rid="f2">Figure 2</xref>).</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Survival of patients with stable angina after coronary artery bypass
grafts (CABG). Overall survival (A, B, and C) and cardiovascular
(CV) survival (D, E, and F). Global population (A and D), diabetic
and non-diabetic patients (B and E), with beta-blocker and without
beta-blocker treatment before surgery (C and F).</p></caption><graphic xlink:href="rbccv-33-01-0047-g01"/></fig>
</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Overall survival in patients with stable angina after coronary artery
bypass grafts (CABG) according to number of internal mammary artery
(IMA) bypass done. AMI = acute myocardial infarction.</p></caption><graphic xlink:href="rbccv-33-01-0047-g02"/></fig>
</p><p>Predictors for overall survival after Cox regression analysis were: hypertension
(hazard ratio [HR] = 2.60, 95%CI: 6.71-1.01), diabetes (HR = 2.07,
95%CI: 3.57-1.20), and age (HR = 1.06, 95%CI:1.03-1.09) (<xref ref-type="table" rid="t3">Table 3</xref>). Predictors for cardiovascular survival after Cox
regression were: use of beta-blockers (HR = 0.43, 95%CI: 1.00-0.18), diabetes
(HR = 2.36, 95%CI: 5.93-1.04), and age (HR = 1.08, 95%CI: 1.03-1.13) (<xref ref-type="table" rid="t4">Table 4</xref>).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Predictors for overall survival in patients who underwent CABG for stable
angina (n = 282).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Predictors</th><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="center" rowspan="1" colspan="1">2.60 (6.71-1.01)</td><td align="center" rowspan="1" colspan="1">0.049</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">2.07 (3.57-1.20)</td><td align="center" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">1.06 (1.03-1.09)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>CABG=coronary artery bypass grafts; CI=confidence interval; HR=hazard
ratio</p></fn></table-wrap-foot></table-wrap><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Predictors for cardiovascular survival in patients who underwent CABG for
stable angina (n=282).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Predictors</th><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Use of beta-blockers</td><td align="center" rowspan="1" colspan="1">0.43 (1.00-0.18)</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">2.36 (5.88-1.04)</td><td align="center" rowspan="1" colspan="1">0.05</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">1.08 (1.03-1.13)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>CABG=coronary artery bypass grafts; CI=confidence interval; HR=hazard
ratio</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Secondary Outcomes</title><p>Operative mortality during the study period was 3.5%. The risk for postoperative
complications including stroke was very low (<xref ref-type="table" rid="t5">Table 5</xref>).</p><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Postoperative outcomes of patients who underwent CABG for stable angina
(n=282).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="50%" span="1"/><col width="50%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Postoperative outcome</th><th align="center" rowspan="1" colspan="1">Patients (282)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Operative mortality (%)</td><td align="center" rowspan="1" colspan="1">10 (3.5)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemodialysis (%)</td><td align="center" rowspan="1" colspan="1">2 (0.7)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pneumonia (%)</td><td align="center" rowspan="1" colspan="1">4 (1.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Stroke (%)</td><td align="center" rowspan="1" colspan="1">4 (1.4)</td></tr><tr><td align="left" rowspan="1" colspan="1">TIA (%)</td><td align="center" rowspan="1" colspan="1">17 (6)</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><p>CABG=coronary artery bypass grafts; TIA=transient ischemic attack</p></fn></table-wrap-foot></table-wrap><p>As we mentioned previously, diabetic patients had worse overall and
cardiovascular survivals. When we analyzed only these patients, we found that
use of beta-blockers (HR = 0.39, 95%CI: 0.81-0.19), female gender (HR = 2.71,
95%CI: 1.28-5.74), and age (HR = 1.07, 95%CI: 1.02-1.13) were predictors for
overall survival (<xref ref-type="table" rid="t6">Table 6</xref>). Due to the
low number of patients, we did not perform Cox regression for cardiovascular
survival.</p><table-wrap id="t6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Predictors for overall survival in diabetic patients who underwent CABG
for stable angina (n=109).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="33%" span="1"/><col width="33%" span="1"/><col width="33%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Predictors</th><th align="center" rowspan="1" colspan="1">HR (95% CI)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Use of beta-blockers</td><td align="center" rowspan="1" colspan="1">0.39 (0.81-0.19)</td><td align="center" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">Female</td><td align="center" rowspan="1" colspan="1">2.71 (1.28-5.74)</td><td align="center" rowspan="1" colspan="1">0.009</td></tr><tr><td align="left" rowspan="1" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">1.07 (1.02-1.13)</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.004</td></tr></tbody></table><table-wrap-foot><fn id="TFN6"><p>CABG=coronary artery bypass grafts; CI=confidence interval; HR=hazard
ratio</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Revascularization in high-risk patients with acute coronary syndromes (ACS) (with or
without ST-segment elevation) provides the best outcome with a significant reduction
in death and myocardial infarction<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>. Conversely, the benefit of revascularization among
patients with chronic stable CAD has been called into question<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. Our study included
patients with stable angina in whom more than 75% had three-vessel disease scheduled
for isolated CABG. We were able to show that longterm overall and cardiovascular
survivals after CABG in these patients were excellent. Operative mortality and
postoperative complications were very low. Age, diabetes, and hypertension were
found to be predictors for overall survival. Age, diabetes, and use of beta-blockers
previous to CABG were found to be predictors for cardiovascular survival. In
diabetic patients, the preoperative use of beta-blockers had a strong protective
effect.</p><p>CAD remains the leading cause of mortality in most industrialized countries, although
age-standardized mortality related to this condition has decreased by more than 40%
during the last two decades<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. Half of this decline resulted from prevention and
reduction in major risk factors, whereas the other half has been attributed to
medical treatment and revascularization<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>.</p><p>Previous data has shown that the percentage of patients who are free from angina
after revascularization is much higher than those who remain with medical treatment
exclusively<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>. Extensive review of the literature reveals that in
developed countries, adherence to therapies averages 50%<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>. Therefore,
revascularization represents an important adjunct to the global treatment of a
patient with stable angina.</p><p>Long-term overall survival in our included patients was found to be similar to the
data presented by the ASCERT trial<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>. Most of our patients died from non-cardiovascular
causes, since the 10-year survival was 91.8%.</p><p>Predictors for overall survival found in our study were similar as those already
published<sup>[<xref rid="r16" ref-type="bibr">16</xref>]</sup>. Hypertension and diabetes increased 2.6 and 2 times,
respectively, the risk for overall mortality. Survival curves in diabetic and
non-diabetic patients after surgery are parallel until 3 years after surgery when
both diverge. This may be due to the diminished long-term permeability of vein
grafts in diabetic patients<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. Even though diabetes increases 2.3 times the risk for
cardiovascular survival, the 10-year cardiovascular survival is excellent (85.9%).
In contrast to our findings, other authors have shown than diabetes <italic>per
se</italic> is not an independent predictor for poor prognosis<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>.</p><p>The benefit of preoperative use of beta-blockers in patients undergoing CABG has been
recently debated. Ferguson et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup> evaluated results from the Society of Thoracic
Surgeons National Adult Cardiac Surgery Database, including patients who underwent
surgery between 1996-1998, and they found that the preoperative use of beta-blockers
is associated with an improvement in survival. Some years later, Brinkman et
al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup> used
the same database, including patients operated between 20082012, and found no
survival benefit of preoperative use of betablockers. Both studies differ in two
main issues: preoperative use of beta-blocker (50-60% in the study by Ferguson et
al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup> and
86% in the study by Brinkman et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>) and operative mortality (3% in Ferguson et
al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup> and
1% in Brinkman et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>). Probably, the significantly higher preoperative use
of beta-blockers and lower mortality in the study by Brinkman et
al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>
render it un-powered to show a survival benefit with beta-blockers. Rossi Neto et
al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup> have
shown that the preoperative use of metoprolol is associated with lower levels of
troponin I, but no data regarding survival is presented. Our study reflects the
outcome of a single center where almost 70% of patients were using beta-blockers
previous to CABG. The preoperative use of beta-blockers was found to be associated
with improved overall survival in the unadjusted model and remained an important
predictor for cardiovascular survival after adjusting for other covariates. Its use
was associated with a two-fold increase in cardiovascular survival. Analyzing
survival curves, the beneficial effect of the preoperative use of beta-blockers
occurs in the first months after surgery. Afterwards, both curves are almost
parallel. Diabetic patients were found to be the main subgroup of patients who
obtained benefit from preoperative use of beta-blockers. Although the beneficial use
of beta-blockers on survival of patients with chronic CAD have already been
shown<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>,
the favorable outcome associated with preoperative use in patients scheduled for
CABG is novel and has not been previously shown.</p><p>Use of multiple arterial bypass has shown to improve survival in patients after
CABG<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup>.
This beneficial effect has been shown specially in diabetic
patients<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>. We have found that patients who received more than one
arterial bypass with IMA had improved overall survival. Looking at survival curves,
the beneficial effect of multiple IMA bypass starts approximately five years after
surgery. This may be due to the differential permeability in venous and arterial
conduits after five years. Unluckily, follow-up angiography was not performed in our
patients and therefore firm conclusions regarding this issue cannot be drawn.</p><sec><title>Limitations</title><p>Our study is subjected to limitations of retrospective studies, such as treatment
bias and patient selection.</p><p>Although 282 patients might seem to be a low number of procedures, we were very
strict in the database selection, restricting the inclusion only to patients
with stable angina (no unstable nor acute myocardial infarction
[AMI] scenarios) and isolated CABG. More than 70% of our CABG
cases are acute coronary syndromes.</p><p>Due to the lack of governmental long-term follow-up of patients who underwent
CABG, information regarding longterm adherence to prescription is limited.
Nonetheless, we had 100% of adherence in the first month after surgery. Since
survival curves in patients who took beta-blockers previous to CABG diverged
mainly in the first few months after surgery and remained parallel afterwards,
differences in long-term adherence to prescriptions would probably not explain
these results.</p><p>The number of patients who underwent multiple IMA bypass was too low to do
further analysis regarding its beneficial effect in diabetic population.</p><p>As a retrospective study, the strict use of beta-blockers preoperatively is
uncertain and therefore this might have influenced the survival results.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>CABG is associated with excellent long-term overall and cardiovascular survivals in
patients with stable angina. Among the already known predictors of survival, the
preoperative use of beta-blockers was found to be protective mainly in patients with
diabetes. These results should reinforce the role of CABG in the global treatment of
patients with stable angina.</p><table-wrap id="t8" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">VD</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; drafting the work or revising
it critically for important intellectual content; agreement to be
accountable for all aspects of the work in ensuring that questions
related to the accuracy or integrity of any part of the work are
appropriately investigated and resolved; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DP</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ES</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">GS</td><td align="left" valign="top" rowspan="1" colspan="1">Substantial contributions to the
conception or design of the work; or the acquisition, analysis, or
interpretation of data for the work; final approval of the version
to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">JE</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the work or revising it
critically for important intellectual content; final approval of the
version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at the Instituto Nacional de Cirug&#x000ed;a
Card&#x000ed;aca, Montevideo, Uruguay.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><fn-group><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fraker Jr</surname><given-names>TD</given-names></name><name><surname>Fihn</surname><given-names>SD</given-names></name><collab>2002 Chronic Stable Angina Writing Committee</collab><collab>American College of Cardiology</collab><collab>American Heart Association</collab><name><surname>Gibbons</surname><given-names>RJ</given-names></name><name><surname>Abrams</surname><given-names>J</given-names></name><name><surname>Chatterjee</surname><given-names>K</given-names></name><name><surname>Daley</surname><given-names>J</given-names></name><etal/></person-group><article-title>2007 chronic angina focused update of the ACC/AHA 2002 guidelines
for the management of patients with chronic stable angina: a report of the
American College of Cardiology/American Heart Association Task Force on
Practice Guidelines Writing Group to develop the focused update of the 2002
guidelines for the management of patients with chronic stable
angina</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>50</volume><issue>23</issue><fpage>2264</fpage><lpage>2274</lpage><pub-id pub-id-type="pmid">18061078</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boden</surname><given-names>WE</given-names></name><name><surname>O'Rourke</surname><given-names>RA</given-names></name><name><surname>Teo</surname><given-names>KK</given-names></name><name><surname>Hartigan</surname><given-names>PM</given-names></name><name><surname>Maron</surname><given-names>DJ</given-names></name><name><surname>Kostuk</surname><given-names>WJ</given-names></name><collab>COURAGE Trial Research Group</collab><etal/></person-group><article-title>Optimal medical therapy with or without PCI for stable coronary
disease</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><issue>15</issue><fpage>1503</fpage><lpage>1516</lpage><pub-id pub-id-type="pmid">17387127</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trikalinos</surname><given-names>TA</given-names></name><name><surname>Alsheikh-Ali</surname><given-names>AA</given-names></name><name><surname>Tatsioni</surname><given-names>A</given-names></name><name><surname>Nallamothu</surname><given-names>BK</given-names></name><name><surname>Kent</surname><given-names>DM</given-names></name></person-group><article-title>Percutaneous coronary interventions for non-acute coronary artery
disease: a quantitative 20-year synopsis and a network
meta-analysis</article-title><source>Lancet</source><year>2009</year><volume>373</volume><issue>9667</issue><fpage>911</fpage><lpage>918</lpage><pub-id pub-id-type="pmid">19286090</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frye</surname><given-names>RL</given-names></name><name><surname>August</surname><given-names>P</given-names></name><name><surname>Brooks</surname><given-names>MM</given-names></name><name><surname>Hardison</surname><given-names>RM</given-names></name><name><surname>Kelsey</surname><given-names>SF</given-names></name><name><surname>MacGregor</surname><given-names>JM</given-names></name><etal/><collab>BARI 2D Study Group</collab></person-group><article-title>A randomized trial of therapies for type 2 diabetes and coronary
artery disease</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><issue>24</issue><fpage>2503</fpage><lpage>2515</lpage><pub-id pub-id-type="pmid">19502645</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kereiakes</surname><given-names>DJ</given-names></name><name><surname>Teirstein</surname><given-names>PS</given-names></name><name><surname>Sarembock</surname><given-names>IJ</given-names></name><name><surname>Holmes Jr</surname><given-names>DR</given-names></name><name><surname>Krucoff</surname><given-names>MW</given-names></name><name><surname>O'Neill</surname><given-names>WW</given-names></name><etal/></person-group><article-title>The truth and consequences of the COURAGE trial</article-title><source>J Am Coll Cardiol</source><year>2007</year><volume>50</volume><issue>16</issue><fpage>1598</fpage><lpage>1603</lpage><pub-id pub-id-type="pmid">17936161</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Windecker</surname><given-names>S</given-names></name><name><surname>Stortecky</surname><given-names>S</given-names></name><name><surname>Stefanini</surname><given-names>GG</given-names></name><name><surname>Costa</surname><given-names>BR</given-names></name><name><surname>Rutjes</surname><given-names>AW</given-names></name><name><surname>Di Nisio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Revascularisation versus medical treatment in patients with
stable coronary artery disease: network meta-analysis</article-title><source>BMJ</source><year>2014</year><volume>348</volume><elocation-id>g3859</elocation-id><pub-id pub-id-type="pmid">24958153</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mancini</surname><given-names>GB</given-names></name><name><surname>Farkouh</surname><given-names>ME</given-names></name><name><surname>Brooks</surname><given-names>MM</given-names></name><name><surname>Chaitman</surname><given-names>BR</given-names></name><name><surname>Boden</surname><given-names>WE</given-names></name><name><surname>Vlachos</surname><given-names>H</given-names></name><etal/></person-group><article-title>Medical treatment and revascularization options in patients with
type 2 diabetes and coronary disease</article-title><source>J Am Coll Cardiol</source><year>2016</year><volume>68</volume><issue>10</issue><fpage>985</fpage><lpage>995</lpage><pub-id pub-id-type="pmid">27585501</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Ancona</surname><given-names>G</given-names></name><name><surname>Karamanoukian</surname><given-names>HL</given-names></name><name><surname>Ricci</surname><given-names>M</given-names></name><name><surname>Schmid</surname><given-names>S</given-names></name><name><surname>Bergsland</surname><given-names>J</given-names></name><name><surname>Salerno</surname><given-names>TA</given-names></name></person-group><article-title>Graft revision after transit time flow measurement in off-pump
coronary artery bypass grafting</article-title><source>Eur J Cardiothorac Surg</source><year>2000</year><volume>17</volume><issue>3</issue><fpage>287</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">10758390</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassand</surname><given-names>JP</given-names></name><name><surname>Hamm</surname><given-names>CW</given-names></name><name><surname>Ardissino</surname><given-names>D</given-names></name><name><surname>Boersma</surname><given-names>E</given-names></name><name><surname>Budaj</surname><given-names>A</given-names></name><name><surname>Fernandez- Avil&#x000e9;s</surname><given-names>F</given-names></name><etal/></person-group><article-title>Task Force for Diagnosis and Treatment of Non-ST-Segment
Elevation Acute Coronary Syndromes of European Society of Cardiology.
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute
coronary syndromes</article-title><source>Eur Heart J</source><year>2007</year><volume>28</volume><issue>13</issue><fpage>1598</fpage><lpage>1660</lpage><pub-id pub-id-type="pmid">17569677</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silber</surname><given-names>S</given-names></name><name><surname>Albertsson</surname><given-names>P</given-names></name><name><surname>Avil&#x000e9;s</surname><given-names>FF</given-names></name><name><surname>Camici</surname><given-names>PG</given-names></name><name><surname>Colombo</surname><given-names>A</given-names></name><name><surname>Hamm</surname><given-names>C</given-names></name><etal/><collab>Task Force for Percutaneous Coronary Interventions of the European
Society of Cardiology</collab></person-group><article-title>Guidelines for percutaneous coronary interventions. The Task
Force for Percutaneous Coronary Interventions of the European Society of
Cardiology</article-title><source>Eur Heart J</source><year>2005</year><volume>26</volume><issue>8</issue><fpage>804</fpage><lpage>847</lpage><pub-id pub-id-type="pmid">15769784</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lloyd-Jones</surname><given-names>D</given-names></name><name><surname>Adams</surname><given-names>R</given-names></name><name><surname>Carnethon</surname><given-names>M</given-names></name><name><surname>De Simone</surname><given-names>G</given-names></name><name><surname>Ferguson</surname><given-names>TB</given-names></name><name><surname>Flegal</surname><given-names>K</given-names></name><etal/><collab>American Heart Association Statistics Committee and Stroke
Statistics Subcommittee</collab></person-group><article-title>Heart disease and stroke statistics: 2009 update: a report from
the American Heart Association Statistics Committee and Stroke Statistics
Subcommittee</article-title><source>Circulation</source><year>2009</year><volume>119</volume><issue>3</issue><fpage>480</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">19171871</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ford</surname><given-names>ES</given-names></name><name><surname>Ajani</surname><given-names>UA</given-names></name><name><surname>Croft</surname><given-names>JB</given-names></name><name><surname>Critchley</surname><given-names>JA</given-names></name><name><surname>Labarthe</surname><given-names>DR</given-names></name><name><surname>Kottke</surname><given-names>TE</given-names></name><etal/></person-group><article-title>Explaining the decrease in U.S. deaths from coronary disease,
1980-2000</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><issue>23</issue><fpage>2388</fpage><lpage>2398</lpage><pub-id pub-id-type="pmid">17554120</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simoons</surname><given-names>ML</given-names></name><name><surname>Windecker</surname><given-names>S</given-names></name></person-group><article-title>Controversies in cardiovascular medicine: chronic stable coronary
artery disease: drugs vs. revascularization</article-title><source>Eur Heart J</source><year>2010</year><volume>31</volume><issue>5</issue><fpage>530</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">20106842</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Health Organization</collab></person-group><year>2003</year><source>Adherence to long term therapies: evidence for action</source><date-in-citation content-type="access-date">2010 June 06</date-in-citation><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/chronic_conditions/en/adherence_report.pdf">http://www.who.int/chronic_conditions/en/adherence_report.pdf</ext-link></comment></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weintraub</surname><given-names>WS</given-names></name><name><surname>Grau-Sepulveda</surname><given-names>MV</given-names></name><name><surname>Weiss</surname><given-names>JM</given-names></name><name><surname>O'Brien</surname><given-names>SM</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name><name><surname>Kolm</surname><given-names>P</given-names></name><etal/></person-group><article-title>Comparative effectiveness of revascularization
strategies</article-title><source>N Engl J Med</source><year>2012</year><volume>366</volume><issue>16</issue><fpage>1467</fpage><lpage>1476</lpage><pub-id pub-id-type="pmid">22452338</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weintraub</surname><given-names>WS</given-names></name><name><surname>Clements Jr</surname><given-names>SD</given-names></name><name><surname>Crisco</surname><given-names>LV</given-names></name><name><surname>Guyton</surname><given-names>RA</given-names></name><name><surname>Craver</surname><given-names>JM</given-names></name><name><surname>Jones</surname><given-names>EL</given-names></name><etal/></person-group><article-title>Twenty-year survival after coronary artery surgery: an
institutional perspective from Emory University</article-title><source>Circulation</source><year>2003</year><volume>107</volume><issue>9</issue><fpage>1271</fpage><lpage>1277</lpage><pub-id pub-id-type="pmid">12628947</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alderman</surname><given-names>EL</given-names></name><name><surname>Corley</surname><given-names>SD</given-names></name><name><surname>Fisher</surname><given-names>LD</given-names></name><name><surname>Chaitman</surname><given-names>BR</given-names></name><name><surname>Faxon</surname><given-names>DP</given-names></name><name><surname>Foster</surname><given-names>ED</given-names></name><etal/></person-group><article-title>Five-year angiographic follow-up of factors associated with
progression of coronary artery disease in the Coronary Artery Surgery Study
(CASS). CASS Participating Investigators and Staff</article-title><source>J Am Coll Cardiol</source><year>1993</year><volume>22</volume><issue>4</issue><fpage>1141</fpage><lpage>1154</lpage><pub-id pub-id-type="pmid">8409054</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>KA</given-names></name><name><surname>Berto</surname><given-names>B</given-names></name><name><surname>Sousa</surname><given-names>AG</given-names></name><name><surname>Costa</surname><given-names>FA</given-names></name></person-group><article-title>Prognosis and complications of diabetic patients undergoing
isolated coronary artery bypass surgery</article-title><source>Braz J Cardiovasc Surg</source><year>2016</year><volume>31</volume><issue>1</issue><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">27074269</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferguson Jr</surname><given-names>TB</given-names></name><name><surname>Coombs</surname><given-names>LP</given-names></name><name><surname>Peterson</surname><given-names>ED</given-names></name><collab>Society of Thoracic Surgeons National Adult Cardiac Surgery
Database</collab></person-group><article-title>Preoperative beta-blocker use and mortality and morbidity
following CABG surgery in North America</article-title><source>JAMA</source><year>2002</year><volume>287</volume><issue>17</issue><fpage>2221</fpage><lpage>2227</lpage><pub-id pub-id-type="pmid">11980522</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brinkman</surname><given-names>W</given-names></name><name><surname>Herbert</surname><given-names>MA</given-names></name><name><surname>O'Brien</surname><given-names>S</given-names></name><name><surname>Filardo</surname><given-names>G</given-names></name><name><surname>Prince</surname><given-names>S</given-names></name><name><surname>Dewey</surname><given-names>T</given-names></name><etal/></person-group><article-title>Preoperative &#x003b2;-blocker use in coronary artery bypass
grafting surgery: national database analysis</article-title><source>JAMA Intern Med</source><year>2014</year><volume>174</volume><issue>8</issue><fpage>1320</fpage><lpage>1327</lpage><pub-id pub-id-type="pmid">24934977</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rossi Neto</surname><given-names>JM</given-names></name><name><surname>Gun</surname><given-names>C</given-names></name><name><surname>Ramos</surname><given-names>RF</given-names></name><name><surname>Almeida</surname><given-names>AF</given-names></name><name><surname>Issa</surname><given-names>M</given-names></name><name><surname>Amato</surname><given-names>VL</given-names></name><etal/></person-group><article-title>Myocardial protection with prophylactic oral metoprolol during
coronary artery bypass grafting surgery: evaluation by troponin
I</article-title><source>Rev Bras Cir Cardiovasc</source><year>2013</year><volume>28</volume><issue>4</issue><fpage>449</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">24598948</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jonas</surname><given-names>M</given-names></name><name><surname>Reicher-Reiss</surname><given-names>H</given-names></name><name><surname>Boyko</surname><given-names>V</given-names></name><name><surname>Shotan</surname><given-names>A</given-names></name><name><surname>Mandelzweig</surname><given-names>L</given-names></name><name><surname>Goldbourt</surname><given-names>U</given-names></name><etal/></person-group><article-title>Usefulness of beta-blocker therapy in patients with
non-insulindependent diabetes mellitus and coronary artery disease.
Bezafibrate Infarction Prevention (BIP) Study Group</article-title><source>Am J Cardiol</source><year>1996</year><volume>77</volume><issue>15</issue><fpage>1273</fpage><lpage>1277</lpage><pub-id pub-id-type="pmid">8677865</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habib</surname><given-names>RH</given-names></name><name><surname>Dimitrova</surname><given-names>KR</given-names></name><name><surname>Badour</surname><given-names>SA</given-names></name><name><surname>Yammine</surname><given-names>MB</given-names></name><name><surname>El-Hage-Sleiman</surname><given-names>AK</given-names></name><name><surname>Hoffman</surname><given-names>DM</given-names></name><etal/></person-group><article-title>CABG versus PCI: greater benefit in long-term outcomes with
multiple arterial bypass grafting</article-title><source>J Am Coll Cardiol</source><year>2015</year><volume>66</volume><issue>13</issue><fpage>1417</fpage><lpage>1427</lpage><pub-id pub-id-type="pmid">26403338</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martins</surname><given-names>SK</given-names></name><name><surname>Santos</surname><given-names>MA</given-names></name><name><surname>Tirado</surname><given-names>FH</given-names></name><name><surname>Martins Jr</surname><given-names>FC</given-names></name><name><surname>Malat</surname><given-names>HF</given-names></name><name><surname>Jatene</surname><given-names>AD</given-names></name><etal/></person-group><article-title>Coronary artery bypass grafting using both internal mammary
arteries in patients with diabetes mellitus</article-title><source>Rev Bras Cir Cardiovasc</source><year>2007</year><volume>22</volume><issue>3</issue><fpage>291</fpage><lpage>296</lpage><pub-id pub-id-type="pmid">18157414</pub-id></element-citation></ref></ref-list></back></article>